Gastroenterology

Gastroenterology

Volume 110, Issue 5, May 1996, Pages 1553-1563
Gastroenterology

Tauroursodeoxycholic acid activates protein kinase C in isolated rat hepatocytes

https://doi.org/10.1053/gast.1996.v110.pm8613063Get rights and content

Abstract

BACKGROUND & AIMS: Ursodeoxycholic acid (UDCA) improves liver function in patients with chronic cholestatic liver diseases by an unknown mechanism. UDCA is conjugated to taurine in vivo, and tauroursodeoxycholic acid (TUDCA) is a potent hepatocellular Ca2+ agonist and stimulates biliary exocytosis and hepatocellular Ca2+ influx, both of which are defective in experimental cholestasis. Protein kinase C (PKC) mediates stimulation of exocytosis in the liver. The aim of this study was to determine the effects of TUDCA on PKC in isolated hepatocytes. METHODS: The effect of TUDCA on the distribution of PKC isoenzymes within the hepatocyte was studied using immunoblotting and immunofluorescence techniques. In addition, the effect of TUDCA on the accummulation of sn-1,2-diacylglycerol (DAG), the intracellular activator of PKC, and hepatocellular PKC activity was studied using radioenzymatic techniques. RESULTS: Immunoblotting studies showed the presence of four isoenzymes (alpha, delta, epsilon, and zeta). The phorbol ester phorbol 12-myristate 13-acetate (1 mumol/L) induced translocation of alpha-PKC, delta-PKC, and epsilon-PKC from cytosol to a particulate membrane fraction, a key step for activation of PKC. TUDCA, but not taurocholic acid, selectively induced translocation of the alpha-PKC isoenzyme from cytosol to the membranes. In addition, TUDCA induced a significant increase in hepatocellular DAG mass and stimulated membrane-associated PKC activity. CONCLUSIONS: TUDCA might stimulate Ca(2+)-dependent hepatocellular exocytosis into bile in part by activation of alpha-PKC. (Gastroenterology 1996 May;110(5):1553-63)

References (0)

Cited by (131)

  • Ursodeoxycholic acid in pregnancy?

    2019, Journal of Hepatology
  • Role of Bile Acids and the Biliary HCO <inf>3</inf><sup>−</sup> Umbrella in the Pathogenesis of Primary Biliary Cholangitis

    2018, Clinics in Liver Disease
    Citation Excerpt :

    TMEM16A regulates anion permeability via protein kinase C alpha (PKCα)- and Ca2+-dependent mechanisms, leading to the dominant chloride gradient that drives AE2-mediated Cl−/HCO3− exchange.45 UDCA, the standard treatment for patients with PBC, which is also applied in various other cholestatic liver diseases owing to its potent anticholestatic effects, stimulates PKCα- and Ca2+-dependent Cl− and HCO3− secretion of cholangiocytes via activation of TMEM16A,42,46 a mechanism of action similar to that unraveled for hepatocytes 2 decades ago.47–50 Insulin receptors are localized in the apical membrane of cholangiocytes and are activated by insulin and insulin-like growth factor present in bile.51

  • Bile Formation and the Enterohepatic Circulation

    2018, Physiology of the Gastrointestinal Tract, Sixth Edition
  • New paradigms in the treatment of hepatic cholestasis: From UDCA to FXR, PXR and beyond

    2015, Journal of Hepatology
    Citation Excerpt :

    Early after the first peer-reviewed reports on UDCA in PBC [7,8] it was proposed that UDCA exerts its hepatoprotective effects in cholestatic liver disease mainly by stimulating impaired hepatobiliary secretion [30]. In the 1990’s, UDCA was then unraveled as a potent intracellular signaling molecule acting as a Ca2+ agonist [31–34] and an activator of protein kinase C (cPKCα) [35–37], mitogen-activated protein kinases (MAPK: Erk1/2, p38MAPK) [38,39] and α5β1 integrins [40,41] in hepatocytes. It was earlier proposed [33,42] and later experimentally proven that UDCA conjugates as potent signaling molecules that might stimulate secretion of hepatocytes (and cholangiocytes [43]) by activating vesicular exocytosis and carrier insertion into their apical membranes resulting in choleretic effects via a dual MAPK- and integrin-dependent mechanism in healthy liver [39,40] and in anticholestatic effects via Ca2+-/type II inositol-1,3,4-triphosphate receptor/cPKCα/PKA-dependent mechanisms in cholestatic liver [44–46].

View all citing articles on Scopus
View full text